Xusbir (Sofosbuvir)

Quote












Anonymous said:
I think its Xusbur but I'm not 100% sure.
Click to expand...

I really like the name. We are going to dominate the market. Slow at first, mainly because there are not that many treating with IFN. Although every GI has one or two that are waiting for Xusbir/Xusbur? I expect the company to double estimates of 2B to around 4B.
 






Anonymous said:
I really like the name. We are going to dominate the market. Slow at first, mainly because there are not that many treating with IFN. Although every GI has one or two that are waiting for Xusbir/Xusbur? I expect the company to double estimates of 2B to around 4B.
Click to expand...

The name is Xusbir. My investigator told me last week.
 
















































Anonymous said:
Great drug...horrible name.
Click to expand...
We will all see if you can dominate without lying and cheating and being unethical. Do something to make you respectable and be able to look at yourself in the mirror and respect yourself. Lots of stuff in this world dominates, but do it the right way-not by encouraging off label usage in 2014 for $$$$$$$$$$
 
























So does it sound like "Zusbir"? If so, why not just spell it that way. You'll be spending half of your time teaching prescribers how to pronounce it. John Martin must have thought this one up himself.
 






Gilead hired a majority of PCP reps instead of experienced HCV reps because they have 11 billion to recoup (buy vs. build mindset) so they can't afford to pay for experience and will nickle and dime all of the new hires while holding their feet to the fire for the rest of their time there (I know cause I was a HBV rep there and lived it first hand). The PCP reps they hired are so overeager that they'll piss of 80% of the HCV treaters within the first 6 months and close the still open accounts to all GI and ID reps in the future. History repeats itself here. Zusbir, Xusbir, Sofosbuvir......doesn't matter, your arrogance and lack of understanding of the market will doom it.
 






Anonymous said:
Gilead hired a majority of PCP reps instead of experienced HCV reps because they have 11 billion to recoup (buy vs. build mindset) so they can't afford to pay for experience and will nickle and dime all of the new hires while holding their feet to the fire for the rest of their time there (I know cause I was a HBV rep there and lived it first hand). The PCP reps they hired are so overeager that they'll piss of 80% of the HCV treaters within the first 6 months and close the still open accounts to all GI and ID reps in the future. History repeats itself here. Zusbir, Xusbir, Sofosbuvir......doesn't matter, your arrogance and lack of understanding of the market will doom it.
Click to expand...

You think your Ritonavir boasted crapola will be any challenge to Xusbir honey?
 






Anonymous said:
Gilead hired a majority of PCP reps instead of experienced HCV reps because they have 11 billion to recoup (buy vs. build mindset) so they can't afford to pay for experience and will nickle and dime all of the new hires while holding their feet to the fire for the rest of their time there (I know cause I was a HBV rep there and lived it first hand). The PCP reps they hired are so overeager that they'll piss of 80% of the HCV treaters within the first 6 months and close the still open accounts to all GI and ID reps in the future. History repeats itself here. Zusbir, Xusbir, Sofosbuvir......doesn't matter, your arrogance and lack of understanding of the market will doom it.
Click to expand...

You are retarded if you think Gilead would "skimp" on reps by hiring inexperienced reps to save on salaries lol...simple math

Lets explore your theory...

Marginal Cost of Experienced Rep base salary: (130k/year HCV rep vs 100k/yr PCP) = $30,000/rep

150 reps x 30k per HCV experienced rep= $4.5 million/yr extra for HCV rep. vs PCP

2014 U.S. Sales ($1.7B average analyst projection x 40% U.S>) = $680 million U.S. Sales

Ratio of U.S. 2014 Sales to marginal Salary Spend: $680m/4.5m = 150X

A 150x multiplier on sales vs. marginal salary..hmmmm

Gilead did not get to be the #2 SP500 performer in the last 25 years by being stupid. With +/- $4.5m for "experienced specialty" pharma reps vs PCP reps, and +/- $68M for each relative 10% to the baseline scenario...

I am pretty damn sure GILD didn't skimp on reps or their salaries...and if you aren't intelligent enough to deduce that yourself..that explains why you lack the intelligence to get hired by GILD.
 






Anonymous said:
You are retarded if you think Gilead would "skimp" on reps by hiring inexperienced reps to save on salaries lol...simple math

Lets explore your theory...

Marginal Cost of Experienced Rep base salary: (130k/year HCV rep vs 100k/yr PCP) = $30,000/rep

150 reps x 30k per HCV experienced rep= $4.5 million/yr extra for HCV rep. vs PCP

2014 U.S. Sales ($1.7B average analyst projection x 40% U.S>) = $680 million U.S. Sales

Ratio of U.S. 2014 Sales to marginal Salary Spend: $680m/4.5m = 150X

A 150x multiplier on sales vs. marginal salary..hmmmm

Gilead did not get to be the #2 SP500 performer in the last 25 years by being stupid. With +/- $4.5m for "experienced specialty" pharma reps vs PCP reps, and +/- $68M for each relative 10% to the baseline scenario...

I am pretty damn sure GILD didn't skimp on reps or their salaries...and if you aren't intelligent enough to deduce that yourself..that explains why you lack the intelligence to get hired by GILD.
Click to expand...

Ok Einstein, thanks for the tutorial on how a drug company establishes a sales force...I was hired and turned it down with no regrets. And yes, they did skim on salaries and some reps - when a KOL tells me that they're already torked off by the new Gilead rep because they act like their entitled to meet with the HCP, there is a problem. I've been in pharma/biotech long enough to figure out that staying ahead of the pack and not following the lemmings is the key to success.
 






Top Bottom
Back
Quote